BIOA
BioAge Labs, Inc.
$15.51
-1.21%
$689.5M
No data for this timeframe.
Vol
Market Cap$689.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders8 funds
Inst. Value$31.0M
Inst. Activity4 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$296.5K
SEC Reports4
Press Releases2
Recent Activity
May 22, 2026
other
BioAge Labs to Present at Upcoming Investor Conferences
<p align="justify">EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:
May 8, 2026
SEC
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $
8-K — Impact 7/10
Apr 23, 2026
Insider
GOLDSTEIN DOV A MD sold 3,542 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 23, 2026
Insider
GOLDSTEIN DOV A MD sold 3,542 shares
Chief Financial Officer @ $4.38 ($15.5K)
Apr 21, 2026
SEC
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify the appointment of KPM
DEFA14A — Impact 3/10
Apr 21, 2026
Press
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsC
Impact 8/10
Apr 1, 2026
SEC
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares of common stock, exe
144 — Impact 3/10
Apr 1, 2026
Insider
RUBIN PAUL D sold 5,437 shares
Chief Medical Officer @ $0.00 ($0.00)
Price Targets
$49.50
+213.3% upside
Strong Buy
Current $15.80
Low $23.00
Median $51.00
High $73.00
8 analysts
$23.00
$73.00
Analyst Ratings
6Strong Buy
6Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Roth Capital | INITIATE | Buy |
| May 13, 2026 | BTIG | INITIATE | Buy |
| Mar 27, 2026 | Needham | INITIATE | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.63 ▲ +1.3% | $-0.75 — $-0.54 | -5% YoY | 6 |
| Next Q | $-0.66 | $-0.85 — $-0.53 | -17% YoY | 6 |
| Current FY | $-2.49 | $-3.03 — $-2.12 | -11% YoY | 7 |
| Next FY | $-2.06 ▲ +25.8% | $-3.02 — $1.15 | 17% YoY | 7 |
Latest Reports
BULLISH
8-K
7/10
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $
May 8, 2026
NEUTRAL
DEFA14A
3/10
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify the appointment of KPM
Apr 21, 2026
BULLISH
Press
8/10
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsC
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $18.7M | DOUBLED |
| MORGAN STANLEY | $4.1M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $2.9M | ADD |
| BANK OF AMERICA CORP | $2.5M | DOUBLED |
| FMR LLC | $1.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 23, 2026 | GOLDSTEIN DOV | M | $0.00 |
| Apr 23, 2026 | GOLDSTEIN DOV | M | $15.5K |
| Apr 1, 2026 | RUBIN PAUL | M | $0.00 |
| Apr 1, 2026 | RUBIN PAUL | SELL | $157.1K |
| Apr 1, 2026 | RUBIN PAUL | M | $22.3K |
8 institutional holders with $31.0M total value (2,339,805 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,414,770 | $18.7M | 60.5% | DOUBLED +123.3% |
| 2 | MORGAN STANLEY | 311,659 | $4.1M | 13.3% | ADD +36.6% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 219,842 | $2.9M | 9.4% | ADD +59.1% |
| 4 | BANK OF AMERICA CORP /DE/ | 188,683 | $2.5M | 8.1% | DOUBLED +1596.9% |
| 5 | FMR LLC | 117,703 | $1.6M | 5.0% | ADD +29.2% |
| 6 | TWO SIGMA INVESTMENTS, LP | 42,151 | $557.7K | 1.8% | TRIM -57.7% |
| 7 | WELLS FARGO & COMPANY/MN | 26,597 | $351.9K | 1.1% | ADD +33.7% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 18,400 | $243.4K | 0.8% | NEAR_EXIT -87.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 228,158 | 311,659 | +36.6% | $4.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 11,119 | 188,683 | +1596.9% | $2.5M | 2025-Q4 |
| FMR LLC | ADD | 91,118 | 117,703 | +29.2% | $1.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 99,669 | 42,151 | -57.7% | $557.7K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 19,888 | 26,597 | +33.7% | $351.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 143,000 | 18,400 | -87.1% | $243.4K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 120,312 | 191,383 | +59.1% | $1.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 89,296 | 143,000 | +60.1% | $840.8K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 64,601 | 99,669 | +54.3% | $586.1K | 2025-Q3 |
| UBS Group AG | ADD | 22,912 | 36,934 | +61.2% | $217.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 15,223 | 19,888 | +30.6% | $116.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 7,602 | 11,119 | +46.3% | $65.4K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 697,667 | 1,557,553 | +123.3% | $6.4M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 29,626 | 213,503 | +620.7% | $881.8K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 89,977 | 120,312 | +33.7% | $496.9K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 89,296 | — | $368.8K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 15,145 | 64,601 | +326.6% | $266.8K | 2025-Q2 |
| UBS Group AG | ADD | 17,803 | 22,912 | +28.7% | $94.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 6,445 | 15,223 | +136.2% | $62.9K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 356,798 | 697,667 | +95.5% | $2.6M | 2025-Q1 |
| FMR LLC | DOUBLED | 7 | 72,307 | +1032857.1% | $271.9K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 442,953 | 29,626 | -93.3% | $111.4K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 103,891 | 17,803 | -82.9% | $66.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 15,145 | — | $56.9K | 2025-Q1 |
| NORGES BANK | EXIT | 27,829 | 0 | -100.0% | $0.00 | 2025-Q1 |
2 unique insiders with 2 transactions. Net insider value: -$296.5K ($0.00 bought, $296.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,542 | $0.00 | $0.00 |
| Apr 23, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,542 | $4.38 | $15.5K |
| Apr 1, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,437 | $0.00 | $0.00 |
| Apr 1, 2026 | RUBIN PAUL D | Chief Medical Officer | SELL | 8,820 | $17.81 | $157.1K |
| Apr 1, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,437 | $4.11 | $22.3K |
| Mar 2, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,433 | $4.11 | $22.3K |
| Mar 2, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,433 | $0.00 | $0.00 |
| Mar 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,542 | $4.38 | $15.5K |
| Mar 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,542 | $0.00 | $0.00 |
| Feb 2, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,433 | $4.11 | $22.3K |
| Feb 2, 2026 | RUBIN PAUL D | Chief Medical Officer | SELL | 7,433 | $18.75 | $139.4K |
| Feb 2, 2026 | RUBIN PAUL D | Chief Medical Officer | M | 5,433 | $0.00 | $0.00 |
| Feb 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,541 | $4.38 | $15.5K |
| Feb 1, 2026 | GOLDSTEIN DOV A MD | Chief Financial Officer | M | 3,541 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.8/10.
BULLISH
8-K
7/10
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $
May 8, 2026
NEUTRAL
DEFA14A
3/10
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify th
Apr 21, 2026
NEUTRAL
144
3/10
Paul Rubin, an officer of BioAge Labs, filed a Form 144 notifying intent to sell up to 8,820 shares
Apr 1, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and Schwab — significantly increased
Feb 28, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 6 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$49.50 mean target
+213.3% upside
Strong Buy (1.67)
$23.00 Low
$73.00 High
| Metric | Value |
|---|---|
| Current Price | $15.80 |
| Target Low | $23.00 |
| Target Mean | $49.50 |
| Target Median | $51.00 |
| Target High | $73.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.63 | $-0.75 | $-0.54 | -5.3% | +1.3% | 3↑ 1↓ | $0.0B | -32.7% | 6 |
| Next Q 2026-09-30 |
$-0.66 | $-0.85 | $-0.53 | -17.2% | — | 2↑ 2↓ | $0.0B | -23.2% | 6 |
| Current FY 2026-12-31 |
$-2.49 | $-3.03 | $-2.12 | -11.3% | — | 3↑ 1↓ | $0.1B | 503.1% | 7 |
| Next FY 2027-12-31 |
$-2.06 | $-3.02 | $1.15 | 17.3% | +25.8% | 3↑ 1↓ | $0.0B | -34.8% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.632 | |
| 7d ago | $-0.636 | +0.004 |
| 30d ago | $-0.640 | +0.008 |
| 60d ago | $-0.640 | +0.008 |
| 90d ago | $-0.674 | +0.042 |
7 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Roth Capital | INITIATE | — | Buy |
| May 13, 2026 | BTIG | INITIATE | — | Buy |
| Mar 27, 2026 | Needham | INITIATE | — | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Feb 18, 2026 | Jefferies | UPGRADE | Hold | Buy |
| Jan 27, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 3 | 0 | 0 | 80% | |
| May 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 5 | 4 | 3 | 0 | 0 | 75% | |
| Feb 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Jan 1, 2026 | 3 | 3 | 4 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
other
BioAge Labs to Present at Upcoming Investor Conferences
<p align="justify">EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage
May 12, 2026
earnings_calendar
BIOA Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
earnings
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="justify"><em>Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in infl
May 4, 2026
fda
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
<p align="justify"><em>Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET</em></p>
May 4, 2026
earnings_calendar
BIOA Q1 2026 Earnings Scheduled — 2026-05-04
Apr 21, 2026
fda
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
<p align="justify"><em>120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and e
Apr 13, 2026
other
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
<p align="justify">EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-sta
Mar 24, 2026
earnings
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
<p align="justify"><em>Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3
Mar 19, 2026
earnings_calendar
BIOA Q4 2025 Earnings Scheduled — 2026-03-19